Dr. Jianping Huang is a leading expert in cancer immunotherapy and neuro-oncology, with more than 20 years of experience advancing immune-based treatments from bench to bedside. Her career has been defined by pioneering work in T cell engineering, translational immunology, and early-phase clinical development.

She is currently a Professor of Neurosurgery at the University of Florida and a former investigator at the National Cancer Institute (NCI), National Institutes of Health (NIH). Her work has contributed to the development of innovative CAR- and TCR-engineered T cell therapies, as well as antibody-based approaches, for both solid tumors and hematologic malignancies.

Dr. Huang has led multiple IND-enabling studies supported by NCI/NIH STTR awards and is the FDA IND holder (IND #32881) for a first-in-human CAR-T cell therapy trial (NCT 05353530) in glioblastoma (GBM), which is now being expanded to additional cancer indications. Under her leadership, these programs have advanced from laboratory discovery to clinical translation, tackling critical challenges of immunotherapy resistance and safety.

Motivated by a mission to overcome immune evasion in cancer, Dr. Huang combines deep immunological insight with clinical urgency to deliver transformative therapies. As Founder and CEO of Immunogenik, she is guiding the company through foundational milestones, advancing a differentiated clinical pipeline, and actively building a world-class team to position its next-generation immunotherapy platforms for global development and commercialization.

‍